key: cord-0788754-657acgl4
authors: Moein, Shima T.; Hashemian, Seyed M.R.; Mansourafshar, Babak; Khorram‐Tousi, Ali; Tabarsi, Payam; Doty, Richard L.
title: Smell dysfunction: a biomarker for COVID‐19
date: 2020-04-17
journal: Int Forum Allergy Rhinol
DOI: 10.1002/alr.22587
sha: a59bda67778e1a3423542c3cb27cbb9f2a1bca47
doc_id: 788754
cord_uid: 657acgl4

BACKGROUND: SARS‐CoV‐2, the virus that causes COVID‐19 disease, is responsible for the largest pandemic since the 1918 H1N1 influenza outbreak. The symptoms presently recognized by the World Health Organization are cough, fever, tiredness, and difficulty breathing. Patient‐reported smell and taste loss has been associated with COVID‐19 infection, yet no empirical olfactory testing on a cohort of COVID‐19 patients has been performed. METHODS: The University of Pennsylvania Smell Identification Test (UPSIT), a well‐validated 40‐odorant test, was administered to 60 confirmed COVID‐19 inpatients and 60 age‐ and sex‐matched controls to assess the magnitude and frequency of their olfactory dysfunction. A mixed effects analysis of variance determined whether meaningful differences in test scores existed between the two groups and if the test scores were differentially influenced by sex. RESULTS: Fifty‐nine (98%) of the 60 patients exhibited some smell dysfunction [mean (95% CI) UPSIT score: 20.98 (19.47,22.48); controls: 34.10 (33.31,34.88); p<0.0001]. Thirty‐five of the 60 patients (58%) were either anosmic (15/60; 25%) or severely microsmic (20/60; 33%); 16 exhibited moderate microsmia (16/60; 27%), 8 mild microsmia (8/60; 13%), and one normosmia (1/60; 2%). Deficits were evident for all 40 UPSIT odorants. No meaningful relationships between the test scores and sex, disease severity, or comorbidities were found. CONCLUSIONS: Quantitative smell testing demonstrates that decreased smell function, but not always anosmia, is a major marker for SARS‐CoV‐2 infection and suggests the possibility that smell testing may help, in some cases, to identify COVID‐19 patients in need of early treatment or quarantine. This article is protected by copyright. All rights reserved

Recently there have been numerous reports in the media that anosmia occurs in persons who have contracted coronavirus disease 2019 (COVID-19) by exposure to the SARS-COV-02 virus. These include one published single case report, 1 and selfreport surveys from Germany, 2 Great Britain, 3 Iran, 4 Italy, 5 and the United States, 6 with smell loss reports ranging from 34% to 68% of COVID-19 positive patients.

Otorhinolaryngology authorities have warned that loss of smell and taste, in combination with other symptoms, appears to be a strong predictor of COVID-19 infection. 7, 8 To date, validated quantitative olfactory testing has not been performed in a cohort of COVID-19 patients to verify or determine the true magnitude of their deficits and whether less-than-total loss occurs in some patients. Moreover, the proportion of COVID-19 patients exhibiting true olfactory disturbances is unknown. Most studies suggest that, in general, a significant number of persons with smell loss are unaware of their deficit until formal testing 9 and that self-reports of both smell and taste abilities correlate poorly with the results of quantitative smell and taste tests. 10, 11 In this case-control study, we administered the Persian version of the 40-item University of Pennsylvania Smell Identification Test (UPSIT) 12 to 60 confirmed Informed written consent was obtained from each patient and control, and the study protocol was approved by the local ethics committee and the Iranian Ministry of Health (license number IR.SBMU.NRITLD.REC.1399.013). All testing was performed with the highest regard for examiner safety with appropriate personal protective equipment.

Daneshvari Hospital. All of the patients underwent 16-slice chest CT imaging (Scope Power Siemens CT Scan, Munich, Germany) and had positive chest CT findings. 13 Subsequently, the diagnosis of COVID-19 disease was confirmed by quantitative detection of SARS-CoV-2 RNA using the real-time reverse transcription polymerase chain reaction (rRT-PCR) in respiratory specimens. 14 prescribed. In patients with progressive COVID-19 disease admitted to the ICU, intravenous immunoglobulin (IVIG) at standard dose of 0.5 g/kg/day daily for 5 days was administered. 16 Olfactory Testing

The Persian version of the 40-odorant University of Pennsylvania Smell Identification Test (UPSIT) was administered in this study (Sensonics International, Haddon Hts., NJ, USA). The UPSIT is a well-validated and reliable (test-retest r = 0.94) test that employs microencapsulated "scratch and sniff" odorants. 11, 12, 17, 18 It provides an index of absolute dysfunction (i.e., anosmia, severe microsmia, moderate microsmia, mild microsmia, normosmia, malingering), as well as relative dysfunction based upon age-and gender-adjusted normative percentile ranks. The total number of odorant stimuli out of 40 that is correctly identified serves as the test measure. Scores on this test correlate well with other types of olfactory tests, including threshold tests. 19 Although the UPSIT is designed to be self-administered, to be certain that the This article is protected by copyright. All rights reserved.

COVID-19 patients correctly performed the test during the limited clinical time window, the testing was assisted by a trained examiner.

Statistical analyses were performed using either SYSTAT 13 20 or MATLAB 2019b (The MathWorks, Inc., Natick, MA, USA). A subject group by gender mixed factor analysis of variance (ANOVA) was used to determine whether the UPSIT scores differed significantly between the patient and control groups and whether gender influenced the test scores. Standard ANOVAs were used to compare other means. Differences in frequencies were assessed using the Fisher's Exact Probability Test.

The COVID-19 patients' non-mutually exclusive presenting symptoms were fever (n = 46, 77%), cough (n = 35, 58%), shortness of breath (n = 31, 52%), headache (n = 22, 37%), myalgia (n = 5, 8%), sweating (n = 2, 3%), shivering (n = 2, 3%), anorexia (n = 2, 3%), stomach ache (n = 1, 2%), and tinnitus (n = 1, 2%). The UPSIT testing revealed that, relative to controls and published normative data, the COVID-19 patients exhibited marked olfactory dysfunction. Thus, as illustrated in Figure 1 , the mean (95% CI) UPSIT score for the COVID-19 patients was 20.98 (19.47, 22.48) , reflecting severe microsmia, 21 whereas the mean UPSIT score (95% CI) for the age- Importantly, all but one of the 60 patients with COVID-19 had some degree of measured olfactory dysfunction (98%). Thirty-five of the 60 patients (58%) were either anosmic (15/60; 25%) or severely microsmic (20/60; 33%); 16/60 (27%) exhibit-ed moderate microsmia, 8/60 (13%) mild microsmia, and 1/60 (2%) normosmia according to UPSIT norms (Table 2) . 21 This contrasts markedly from the controls, of which 49/60 (82%) were normal with the remaining 11/60 (18%) having only mild borderline dysfunction. Relative to the normal controls, the 11 controls with mild borderline dysfunction tended to be disproportionately men [ Thirty-five percent (21/60) of the COVID-19 patients reported a loss in either smell or taste function, with 12% (7/60) reporting smell loss only, 7% (4/60) taste loss only, and 17% (10/60) both taste and smell loss. There was no significant difference between UPSIT scores of patients who were aware or unaware of their chemosensory loss (p = 0.28). All 21 reported that the onset of the olfactory dysfunction occurred at the same time or immediately after the onset of their other COVID-19 symptoms. None reported recognizing any smell or taste deficits prior to their other COVID-19 symptoms, namely fever, cough, or shortness of breath. In the healthy control group, none of the participants reported any smell or taste problems.

As shown in Table 1 

This study quantitatively evaluated olfaction in a sizable cohort of patients diagnosed with the SARS-CoV-2 virus infection. By employing a well-validated 40item smell test, COVID-19 patients were able to be classified into distinct categories of olfactory dysfunction, with 50 of 60 (83%) exhibiting either anosmia or severe microsmia. In the present study, only 35% of the patients were aware of their olfactory deficit before testing, a percentage nearer to that of 34% reported in an interview with COVID-19 inpatients in Italy, 5 but lower than those reported in two online surveys (59% 3 and 68% 6 ). This difference between self-report rate and quantified smell assessment conceivably reflects either a disproportionate sampling of hospital admitted cases or the well-documented underestimation of self-reported smell and taste dysfunction present for the general population 9,10 and for such diseases as Alzheimer's 11 and Parkinson's disease. 22, 23 In general, smell loss is most noticeable when marked loss, such as anosmia, is present. 11, 22 It should be pointed out that the present study's sample resembles the demographic and clinical characteristics of COVID-19 patients reported in a compilation of 43 studies involving 3600 patients, 24 implying it is likely representative of COVID-19 patients in general.

The basis for the smell loss due to SARS-CoV-2 is not entirely clear, although it is well established that viruses and other xenobiotics can damage the olfactory neuroepithelium. Indeed, acute viral upper respiratory viral infections that damage this epithelium are the major cause of chronic olfactory dysfunction and numerous This article is protected by copyright. All rights reserved.

viruses are known to enter the brain through cellular and pericellular transport via this epithelium. 25 In North America, the peak period of non-influenza-related smell loss, including that possibly due to coronaviruses, occurs during the months of April, May, and June, whereas for influenza-related viral loss peaks in December, January and February. 26 Currently, the prevalence of COVID-19 in North America seems to follow a similar function to that observed for olfactory deficits due to other viruses, including other coronaviruses. What seems unique, however, is that nearly everyone who contacts COVID-19 appears to exhibit measurable loss of smell seemingly independent of severe nasal congestion or inflammation.

Although SARS-CoV-2 has the ability to enter epithelial cells by directly binding to the angiotensin converting enzyme 2 (ACE2) protein on the cell surface, 27 olfactory receptor cells do not express ACE2, as well as another gene involved in CoV-2 entry (TMPRSS2), unlike epithelial sustentacular and stem cells. 28 Thus, damage to the olfactory receptors may be mediated indirectly through SARS-CoV-2 uptake into other cells critical for sustaining the olfactory receptor cell population. For example, olfactory ensheathing glial cells that surround the olfactory receptor cell axons and form the olfactory fila are one candidate by which ACE2-independent virus transfer can occur into olfactory receptor neurons by way of exosomes. A possible scenario suggests that at this point olfactory receptor neurons may initiate a rapid immune response in the host with the manifestation of olfactory dysfunction. 29 That being said, the olfactory neuroepithelium has considerable propensity for regeneration if the stem cell layer is not markedly damaged 30-32 -regeneration that is likely related to spontaneous improvement in olfactory function over time. 33 It is of interest that significantly fewer smokers were found in our COVID-19 cohort than in the control cohort. Our findings correspond with studies that report This article is protected by copyright. All rights reserved. current smokers as rare as 1.4% and 1.3% in Chinese 34 and US 35 COVID-19 patient populations, respectively. A recent study reported that smoking upregulated the expression of ACE-2 in the airways, potentially predisposing individuals to increased risk of coronavirus infection but, paradoxically, protecting the host against acute lung injury. 36 Interestingly, non-smokers appear to be much more susceptible than smokers to olfactory dysfunction from industrial exposures to acrylate and methacrylate 37 and smoking appears to protect, to some degree, the olfactory loss of Parkinson's disease. 38 Future research is needed to determine to what degree the reported low frequency of smokers in COVID-19 populations is impacted by selection bias (e.g., more smokers may have died before reaching the hospital) and reverse causation (i.e., cessation of smoking in patients with severe symptoms prior to entering the hospital, thereby being counted as non-smokers). The latter is unlikely in our study, however, since each patient was specifically asked whether they currently smoke or had smoked in the past.

The complaint of taste loss by a small number of our COVID-19 patients most likely reflects, to a significant degree, damage to the olfactory system, rather than damage to the taste buds or taste afferents, per se. Thus, the vast majority of individuals who clinically present with complaints of taste loss actually exhibit smell dysfunction, including those with a viral etiology. 39 Taste bud-mediated sensations are largely limited to the basic taste qualities of sweet, sour, bitter, salty, and umami.

With the exception of such sensations, all "tastes" are flavor sensations from olfactory receptor stimulation by volatiles entering from the nasopharynx during deglutition. 40 This tendency for many persons with smell loss to misconstrue their problem as taste loss 39 must be considered in studies relying only on self-report.

Future research employing quantitative taste tests is clearly needed to definitively establish whether SARS-CoV-2 also can damage taste afferents or, in rare cases, more central taste-related brain regions.

More men than women were present in our sample, in accord with the reported demographic and clinical characteristics of COVID-19 patients. 24 However, the magnitude of olfactory dysfunction, as measured by the UPSIT, was essentially the same in both sexes. This implies that there is little or no protection from being a female in terms of the degree to which SARS-CoV-2 damages the olfactory system, in accord with some other studies of post-viral olfactory deficits. 41 If this observation is confirmed with larger samples, it would appear that the olfactory dysfunction of COVID-19 differs from that of Alzheimer's disease (AD) and Parkinson's disease (PD), where women significantly outperform men. 11, 22, 38 It is important to note that the COVID-19 positive patients evaluated in this study had severe enough symptoms to be admitted to hospital. It is unknown whether less severe cases also exhibit the same degree of smell dysfunction as documented in this study, although within our hospitalized cohort no relationship was evident between the olfactory test scores and disease severity. This is similar to what is seen in the smell loss of PD, where no clear association is present between the magnitude of the classic motor signs and the amount of olfactory dysfunction. 22 Even though the COVID-19 patients in this study were undergoing drug treatments for their disease, it is unlikely that the involved drugs were a meaningful cause of their olfactory dysfunction. Despite the fact that a significant number of medications are reported to have taste side effects, 42 alterations in smell function are relatively rare and have not been associated with hydroxychloroquine, Lipinavir-Ritonavir, or IVIG. Since the same degree of smell function was evident among pa-tients with COVID-19 taking each of these medications, it is improbable that any one medication would have produced the smell deficits observed in this study.

While RT-PCR was by far the frontline response to the SARS-CoV-2 outbreak, the accuracy and conditions under which the results of RT-PCR were achieved must be kept in context, since a false negative rate of at least 15% has been reported. [43] [44] [45] The present findings, along with the wealth of anecdotal data, suggest that quantitative testing of the sense of smell might serve as a rapid and inexpensive alternative diagnostic means to screen for COVID-19 in large numbers of individuals. Indeed, the sensitivity and specificity of olfactory tests for COVID-19

positive patients under the age of 65 would seem to be quite strong, since agerelated changes in smell function occur mainly after the age of 65. 17 The present study has both strengths and weaknesses. smell significantly impacts quality of life, the flavor of foods and beverages, and safe-harbinger of a number of neurological diseases, most notably AD and PD -diseases which, in some cases, have been associated with a number of viruses. 46, 47 While the reasons are poorly understood, older persons with smell loss are three times more likely to die over the course of an ensuring half-decade than older persons with a normal sense of smell. 48, 49 In conclusion, the present study provides a quantitative assessment of the olfactory function of a cohort of patients with COVID-19. Its findings strongly suggest that some degree of loss of smell function is present in nearly all COVID-19 patients 

Sudden and Complete Olfactory Loss Function as a Possible Symptom of COVID-19

The Covid-19 pandemic and otolaryngology: What it comes down to?

Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection

Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak

Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study

Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms

Loss of sense of smell as marker of COVID-19 infection

Unawareness of olfactory dysfunction and its association with cognitive functioning in middle aged and old adults

Accuracy of self-report in detecting taste dysfunction

Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Massachusetts General Hosital COVID-19 Treatment Guidance

A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol

Smell identification ability: changes with age

Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test

Clinical validation of the olfactory detection threshold module of the Snap & Sniff(R) olfactory test system

SYSTAT: The System for Statistics

The Smell Identification Test TM Administration Manual

Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration

This article is protected by copyright. All rights reserved

Odor identification deficit of the parkinsonismdementia complex of Guam: Equivalence to that of Alzheimer's and idiopathic Parkinson's disease

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis

The olfactory vector hypothesis of neurodegenerative disease: is it viable?

Olfactory dysfunction from acute upper respiratory infections: Relationship to season of onset

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

Non-neural expression of SARS-ClV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVD-19 patients

SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection

The balance between efficient anti-inflammatory treatment and neuronal regeneration in the olfactory epithelium

Olfactory epithelium: Cells, clinical disorders, and insights from an adult stem cell niche

Primary Cilia on Horizontal Basal Cells Regulate Regeneration of the Olfactory Epithelium

This article is protected by copyright. All rights reserved

Predictors of prognosis in patients with olfactory disturbance

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus 2910 j--United States

ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19

Olfactory function in chemical workers exposed to acrylate and methacrylate vapors

Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking

Smell and taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste Center

The effects of mouth movements, swallowing, and spitting on retronasal odor perception

Influence of medications on taste and smell

False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases

Eastern China. . medRxiv 2020. medRxiv doi

Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study

Herpes viruses and Alzheimer's disease: new evidence in the debate

Viral mimetic priming enhances alpha-synucleininduced degeneration: Implications for Parkinson's disease

Olfactory dysfunction predicts 5-year mortality in older adults

Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community

We would like to thank Mr. Iraj Fotouhi for his invaluable help in assisting patients during smell testing, Ms. Crystal Wylie for comments on a draft of the paper, and Dr.Kambiz Pourrezaei for insightful discussions of the research.